- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2018
- Public Summary Document (PSD) March 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2018 PBAC Meeting - Word
Omalizumab – March 2018
Omalizumab: prefilled syringe, 150 mg/mL; Xolair®
Last updated
29 June 2018